Lysosomal Alpha Glucosidase Pipeline Review, H2 2019
Summary
According to the recently published report 'Lysosomal Alpha Glucosidase Pipeline Review, H2 2019'; Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.
Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 Lysosomal alphaglucosidase is an enzyme encoded by the GAA gene. It is essential for the degradation of glygogen to glucose in lysosomes. Defects in this gene lead to glycogen storage disease II or Pompe disease.
The report 'Lysosomal Alpha Glucosidase Pipeline Review, H2 2019' outlays comprehensive information on the Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 9 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Pompe Disease.
Scope
The report provides a snapshot of the global therapeutic landscape for Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20
The report reviews Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics and enlists all their major and minor projects
The report assesses Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope